- Reaction score
- 1,936
Gilead said Tuesday that it will soon begin Phase 3 testing for a drug it believes could prevent HIV infection with just a single shot every year.
Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research. The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027.
The once-a-year drug is another formulation of lenacapavir, a medicine that already made headlines this year when Gilead published data showing it could prevent HIV infections with just one shot every six months.
Gilead executives revealed the 12-month formulation at an analyst day dedicated to its HIV portfolio. They said they recently completed a pharmacokinetics study — i.e. tracking how a drug behaves in the body — that gave them confidence to advance the molecule. They will present that data next year.
www.statnews.com
Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research. The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027.
The once-a-year drug is another formulation of lenacapavir, a medicine that already made headlines this year when Gilead published data showing it could prevent HIV infections with just one shot every six months.
Gilead executives revealed the 12-month formulation at an analyst day dedicated to its HIV portfolio. They said they recently completed a pharmacokinetics study — i.e. tracking how a drug behaves in the body — that gave them confidence to advance the molecule. They will present that data next year.
Gilead to test once-a-year HIV prevention shot
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
www.statnews.com
